Company / Cash & Equivalents
Avantor Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$365.4M
FY2025
5-year range
$261.9M / $372.9M
FY2021-FY2025
Trend
+39.5%
vs FY2024
Sector context
#58 of 148
Health Care
What the data says
At $365M, Avantor's cash & equivalents ranks #58 of 148 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $365M.
Based on SEC 10-K filings.
$365M in FY2025 with a 5-year CAGR of +5.0%.
Improved from $263M to $365M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -0.7%
- 5-Year CAGR
- +5.0%
- 10-Year CAGR
- -
Sector benchmark
#58 of 148 in Health CareTop 39% of 148This company $365.4M Sector average $1.2B
▼
-68.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 39.5% year-over-year.
- Ranks #58 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $365.4M | +39.5% |
| FY2024 | $261.9M | -0.4% |
| FY2023 | $262.9M | -29.5% |
| FY2022 | $372.9M | +23.6% |
| FY2021 | $301.7M | +5.3% |
| FY2020 | $286.6M | +53.5% |
| FY2019 | $186.7M | +1.1% |
| FY2018 | $184.7M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026